BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: HLXB) is a clinical-stage biopharmaceutical company focused on oncology that entered the public markets through a special purpose acquisition vehicle structure. The company filed a 424B3 prospectus supplement with the SEC on May 6, 2026, accession number 0001193125-26-208937, a form type typically used post-business-combination to register shares for resale by existing holders. Operating in the healthcare and oncology therapeutics sector, HLXB represents a SPAC-sponsored pathway to public capital for a company developing cancer-focused drug candidates. For the full sponsor profile, deal timeline, IPO year, and real-time filing data on HLXB, sign up for a SpacDesk account at spacdesk.com.